Median Technologies has announced the upcoming showcase of its innovative AI-powered software, eyonis® LCS, designed specifically for lung cancer screening. This presentation will take place at the RSNA Annual Meeting, set for November 25, 2025. The software represents a significant advancement in the early detection of lung cancer, aiming to enhance diagnostic accuracy and improve patient outcomes.
Enhancing Lung Cancer Detection
The eyonis® LCS is classified as a medical device, utilizing artificial intelligence to analyze medical imaging data. This software is expected to assist healthcare professionals in identifying potential lung cancer cases more efficiently than traditional methods. With lung cancer being one of the leading causes of cancer-related deaths worldwide, early detection is crucial for successful treatment.
According to the World Health Organization, lung cancer accounts for approximately 1.8 million deaths annually, underscoring the importance of effective screening tools. Median Technologies aims to address this urgent need by providing a solution that integrates seamlessly into existing clinical workflows.
RSNA Meeting Highlights
The Radiological Society of North America (RSNA) Annual Meeting is a premier event in the medical imaging field, attracting thousands of professionals from around the globe. The conference will serve as a platform for Median Technologies to demonstrate the capabilities of eyonis® LCS, highlighting its potential benefits to both patients and healthcare providers.
Attendees will have the opportunity to engage with the product firsthand, learning about its features and functionalities through live demonstrations. The event is expected to generate significant interest among radiologists, oncologists, and other healthcare professionals eager to adopt cutting-edge technologies in their practice.
As the demand for innovative healthcare solutions continues to grow, Median Technologies remains committed to advancing the field of medical imaging. The introduction of eyonis® LCS is a testament to the company’s dedication to harnessing technology for better health outcomes.
The unveiling of this software at the RSNA Annual Meeting marks a pivotal moment for Median Technologies. By leveraging artificial intelligence, the company aims to make a lasting impact on lung cancer screening and ultimately contribute to saving lives.
